Revaprazan
CAS: 199463-33-7
Ref. 3D-ZHA46333
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued |
Product Information
- 4-(3,4-Dihydro-1-methyl-2(1H)-isoquinolinyl)-N-(4-fluorophenyl)-5,6-dimethyl-2-pyrimidinamine
- YH 1885 free base
- 2-Pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-N-(4-fluorophenyl)-5,6-dimethyl-
- SB 641257
Revaprazan hydrochloride is the salt form of Revaprazan which is concentrated in the gastric parietal cell canaliculus. Due to the acidic environment of the parietal cells, Revaprazan is protonated and binds to and reversibly inhibits H+/K+-ATPase. As a result H+ ions are prevented from entering into the gastric lumen, thus hindering the production of gastric acid. This ability of Revaprazan has enabled it to be used to treat gastric ulcers and gastroesophageal reflux disease. According to the biopharmaceutical classification system, Revaprazan is a class II drug, however it has low oral bioavailability.